
Fluoguide Q3 2023 - Spoilt for choice

Redeye comments on Fluoguide's Q3 2023 report, with the company reporting two solid phase II readouts since our last update. We expect Fluoguide to present its later-stage clinical development plan for FG001 in coming months and do some housekeeping in our model.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Fluoguide Q3 2023 - Spoilt for choice](#)